12:00 AM
 | 
Aug 10, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TH-302: Phase I data

Pooled data from a subgroup of 13 patients with non-small cell lung cancer (NSCLC) in the open-label, dose-escalation, U.S. Phase I TH-CR-401 trial and the dose-escalation Phase I part of the U.S. Phase I/II TH-CR-402 trial showed that TH-302 produced 3 partial responses. One of the patients received TH-302 and...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >